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Abstract
Awareness of cancer therapy-induced toxicities is important
for all clinicians treating patients with cancer. Cancer therapy
has evolved to include classic cytotoxic agents in addition to
newer options such as targeted agents and catheter-directed
chemoembolisation. Several adverse affects can result from
the wide array of treatments including effects on the liver,
pancreas, and biliary system that can be visualised on imag-
ing. These complications include sinusoidal obstruction syn-
drome, fatty liver, pseudocirrhosis, acute hepatitis, pancreati-
tis, pancreatic atrophy, cholecystitis, biliary sclerosis, and bil-
iary stasis. Many of these toxicities are manageable and re-
versible with supportive therapies and/or cessation of cancer
therapy. The objective of this review is to discuss the imaging
findings associated with cancer therapy-induced toxicity of
the liver, biliary system, and pancreas.
Teaching Points
• Cancer therapy can have adverse effects on the hepatobiliary
system and pancreas.
• Cancer therapy-induced toxicities can be visualised on
imaging.
• Knowledge of imaging changes associated with cancer
therapy complications can improve treatment.
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Introduction
Chemotherapy is an essential component in the treatment
of cancer. Systemic cancer therapy has evolved from the
classic cytotoxic agents to now include newer classes of
molecularly targeted therapy. Classic cytotoxic agents tar-
get rapidly proliferating cells by interfering with their cell
division and growth. Newer therapies target specific cancer
molecules involved in regulating cancer cell growth and
differentiation. Additionally, the use of chemoembolisation,
a minimally invasive procedure used to locally administer
chemotherapeutic agents directly to tumours, continues to
grow and is predominantly used in the treatment of liver
cancers.
While these therapies aim to inhibit cancerous tissue
growth, both systemic and localised therapies are known
to have adverse effects on normal tissues. With the vary-
ing mechanisms of action, it is not surprising that the
side effects of different anticancer agents and treatment
modalities are diverse, affecting nearly every organ sys-
tem. Many of the adverse effects of cancer therapy on
the liver, pancreas, and biliary system can be detected on
imaging (Table 1). These include sinusoidal obstruction
syndrome (SOS), fatty liver, pseudocirrhosis, hepatitis,
pancreatitis, pancreatic atrophy, cholecystitis, biliary scle-
rosis, and biliary inflammation. The objective of this
article is to review and discuss the imaging findings
associated with cancer therapy-related changes in the liv-
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Effects of systemic therapy
Liver
Fatty liver
Fatty infiltration of hepatic tissue as well as buildup of fat
globules in hepatocytes is considered hepatic steatosis while
steatohepatitis is a more severe form of fatty liver disease
with hepatocyte degeneration. Steatohepatitis is often
asymptomatic; however, it can often manifest through ele-
vations of alanine transaminase (ALT) and aspartate trans-
aminase (AST). Fatty changes have been linked to the
chemotherapeutic agents oxaliplatin, irinotecan, 5-FU, and
methotrexate with initial steatotic appearance occurring
from 2 weeks to 2 months after therapy [1, 2].
Table 1 Table summarising adverse effects visible on imaging and most commonly associated cancer therapies
Adverse effect Associated therapy Laboratory findings Radiologic findings




US: increased echogenicity and beam
attenuation
CT: reduced liver attenuation






↑ Bilirubin US: ascites, gallbladder wall thickening,
hepatosplenomegaly
CT: ascites, decreased right hepatic vein
diameter (<0.45 cm), perioesophageal
varices, hepatosplenomegaly, and
recanalisation of the umbilical vein
Pseudocirrhosis Gemcitabine None US, CT, MR: segmental volume loss,
capsular retraction, fibrosis, enlargement
of caudate lobe
Acute hepatitis Anastrozole, lapatinib ↑ ALT
↑ AST
US: Bstarry sky^ sign
CT: Hepatosplenomegaly, thickened
gallbladder wall, periportal oedema,
decreased liver enhancement
Hepatic abscess TACE ↑ Alkaline phosphatase
Hypoalbunaemia
CT: hypoattenuating lesion with peripheral
rim enhancement





US: increased echogenicity, ascites, nodularity,
segmental hypertrophy/atrophy
CT: surface and parenchymal nodularity,
segmental hypertrophy/atrophy





US: peripancreatic fluid collection,
hypoechoic lesions
CT: areas of low attenuation, diffuse
pancreatic oedema
Pancreatic atrophy Sorafenib, sunitinib None CT: reduced pancreatic volume
Acute acalculous cholecystitis Everolimus, sunitinib, bevacizumab ↑ Alkaline phosphatase
↑ Bilirubin
US: gall bladder wall thickening, gallbladder
distension, pericholecystic fluid collection
CT: gallbladder distension, fat stranding,
hyperaemia, pericholecystic fluid
Biliary inflammation L-asparaginase, doxorubicin, epirubicin,
paclitaxel
None CT: biliary epithelial thickening and
enhancement
Biliary sclerosis HAIPC w/ floxuridine ↑ Alkaline phosphatase
↑ Bilirubin
CT: thickened/enhanced bile duct wall, bile
duct stricture with lumen <3 mm, periductal
oedema
ERCP: dilatation and stricture of biliary tree









CT: main bile duct dilatation, extrabiliary
collection of bile
MRCP: biliary fluid collection and bile duct
leaks
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Chemotherapy-associated steatohepatitis (CASH) may be
diffuse or focal and can be seen on ultrasound (US) as in-
creased parenchymal echogenicity and beam attenuation [3].
Steatosis may also be visualised on computed tomography
(CT) and is characterised by decreased parenchymal attenua-
tion (Fig. 1) [4]. On magnetic resonance (MR) imaging, fatty
liver can be detected by a drop in signal intensity on opposed-
phase images compared with in-phase images. This is partic-
ularly useful in the diagnosis of focal hepatic steatosis (Fig. 2)
[5, 6]. Detecting and reporting fatty changes on imaging in the
chemotherapy patient is meaningful as it may prompt changes
in treatment, especially in metastatic colorectal cancer patients
who are planned for hepatic metastasectomy as underlying
steatosis may increase the risk for post-operative complica-
tions [7]. Steatotic changes may be reversible with cessation
of therapy and severe cases of CASH may require adjustment
of surgical plans as there is increased hepatopathy, liver failure
(5.8 % vs. 0.8 %), and mortality rate (14.7 % vs. 1.6 %) in
these patients following partial hepatectomy [8, 9].
Sinusoidal obstruction syndrome
Hepatic sinusoidal obstruction syndrome (SOS) is an injury to
the hepatic venous endothelium causing deposition of fibrous
material within the venule walls and liver sinusoids; this de-
position leads to obstruction of small intrahepatic vessels [10].
Clinical presentation of SOS includes hepatosplenomegaly,
jaundice, abdominal pain, and ascites and can be characterised
histologically by sinusoidal fibrosis, sinusoid dilation and
congestion, and necrosis of pericentral hepatocytes [11, 12].
SOS is associated with systemic cancer therapies such as
oxaliplatin, fluorouracil (5-FU), mercaptopurine (6-MP), and
dacarbazine and may present as early as 1 to 3 weeks after
initiation of therapy [13–15].
US findings of chemotherapy-induced SOS include ascites,
gallbladder wall thickening, and hepatosplenomegaly as well
as decreased flow through the portal vein on Doppler US [7].
CT reveals similar findings of hepatosplenomegaly, ascites,
perioesophageal varices, and recanalisation of the umbilical
vein [4]. Post-contrast enhancement CT and MR imaging
commonly reveal patchy liver enhancement and narrowing
of the main hepatic veins [16]. With detection of ascites, it is
important to confirm the diagnosis of SOS as opposed to ma-
lignant ascites associated with peritoneal spread or metastasis
[17]. Malignant ascites account for approximately 10 % of
ascites cases; thus, the distinction between the two is crucial
so that the appropriate treatment steps can be taken [17].
Pseudocirrhosis
Pseudocirrhosis describes changes in hepatic contour, such as
the development of diffuse hepatic nodularity, in patients fol-
lowing chemotherapy treatment for hepatic metastases [18].
Pseudocirrhosis is most commonly found following chemo-
therapy with gemcitabine in patients treated for metastatic
breast cancer [19]. While the majority of the clinical features
associated with cirrhosis are absent in pseudocirrhosis, portal
hypertensionmay be present [4]. Qayyum reports hepatic con-
tour changes in 75% of patients being treated for breast cancer
metastasis, with 9 % of patients showing signs and symptoms
of portal hypertension [20].
The morphologic changes characteristic of pseudocirrhosis
are initially detected between 4 and 8 months after therapy,
may be diffuse or focal, and mimic liver cirrhosis, causing
segmental volume loss, capsular retraction, fibrosis, and en-
largement of the caudate lobe on US, CT, and MR imaging
(Fig. 3) [18, 19, 21]. Additionally, the imaging findings of
portal hypertension such as ascites, portosystemic venous col-
laterals, and splenomegaly may also be present [22]. CT is
generally the modality of choice for detecting the features of
Fig. 1 A 61-year-old male with colon cancer undergoing systemic
treatment with oxaliplatin. a Axial contrast-enhanced CT pre-
chemotherapy shows normal findings. b Axial CT status post 3 months
of treatment with oxaliplatin shows development of diffuse fatty
infiltration with hyperattenuating intrahepatic vessels consistent with
steatosis
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pseudocirrhosis; however, MRI is more sensitive than CT
for the follow-up of liver metastases and is recommended
in these patients. While the exact mechanism underlying
pseudocirrhosis is not fully understood, it has been linked
with complications of hepatic encephalopathy, variceal
bleeding, and portal hypertension [4]. Discontinuation of
chemotherapy may be warranted if pseudocirrhotic compli-
cations cannot be managed conservatively [19].
Acute hepatitis
Recent literature has demonstrated an association between acute
hepatitis and several targeted therapies such as anastrozole and
lapatinib [8]. Additionally, reactivation of hepatitis B has been
Fig. 2 A 60-year-old female with colorectal cancer currently being
treated with irinotecan. a, b Axial T1-weighted MR images in and out
of phase, respectively, show significant signal drop in the liver consistent
with steatosis
Fig. 3 A 48-year-old female with metastatic breast cancer status post
treatment with docetaxel and epirubicin. a Axial contrast-enhanced CT
before chemotherapy shows normal-appearing liver with a smooth
surface. b Repeat CT 6 months after initiation of treatment shows
nodularity of the left hepatic lobe. c Repeat CT 7 months after initiation
of treatment shows diffuse nodularity and capsular retraction consistent
with pseudocirrhosis
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observed following treatment with rituximab, alemtuzumab,
and infliximab [23]. Reactivation of hepatitis C has been ob-
served with rituximab, alemtuzumab, and gemcitabine [24].
The presentation of acute hepatitis may range from asymptom-
atic to severe with nausea, poor appetite, vomiting, right upper
quadrant pain, and jaundice with elevated ASTand ALT. In the
majority of patients, hepatitis is improved and reversible with
temporary cessation of cancer therapy [2].
In patients with acute hepatitis, ultrasound demonstrates
multiple echogenic foci within a relatively hypoechoic liver
parenchyma, the so-called Bstarry sky^ sign (Fig. 4) [25]. CT
findings of acute hepatitis are nonspecific and include
hepatosplenomegaly, thickened gallbladder wall, periportal
oedema, and decreased liver enhancement (Fig. 5) [26].
Pancreas
Pancreatitis
Chemotherapy-induced pancreatitis is well documented in
the literature and is associated with several chemothera-
peutic agents. These chemotherapeutic agents include L-
asparaginase, carboplatin cisplatin, cytarabine, ifosfamide,
paclitaxel, tretinoin, and vinorelbine [27, 28]. The onset
of pancreatitis is variable and may range from hours to
1 month after drug administration [27].
Among the listed agents, chemotherapy-induced pancrea-
titis is most closely associated with asparaginase therapy with
a prevalence of 2–16 % [7, 29]. L-asparaginase is a cytotoxic
chemotherapeutic agent commonly used in the treatment
of acute lymphocytic leukaemia. Additionally, a correlation
between the targeted tyrosine kinase inhibitors sorafenib
and sunitinib and pancreatitis has been described in recent
literature [29]. Motzer et al. examined the effects of suni-
tinib in patients with metastatic renal cell carcinoma and
reported elevated serum lipase in 30 % of patients without
any other clinical signs of pancreatitis [30]. In another
study, clinical pancreatitis was found in 3 of 451 patients
on sorafenib with several other documented case reports of
sorafenib-induced pancreatitis that resolved with discontin-
uation or reduction in sorafenib dosing [31–33].
For detecting and grading the severity of acute pancreatitis,
multi-detector computed tomography (MDCT) is themodality
of choice. Chemotherapeutic agents first cause acute intersti-
tial pancreatitis, which may further progress to acute
necrotising pancreatitis. On CT, acute interstitial pancreatitis
may be characterised by fluid collections, peripancreatic fat
stranding, focal areas of decreased attenuation, or diffuse
Fig. 4 A 63-year-old female with metastatic breast cancer undergoing
treatment with a drug regimen that includes lapatinib. Longitudinal US of
the liver reveals diffuse starry sky appearance consistent with diffuse
hepatic oedema and acute hepatitis
Fig. 5 A 54-year-old male with acute myelogenous leukaemia treated
with alemtuzumab. a, b Axial and coronal contrast-enhanced CT images,
respectively, demonstrating hepatomegaly and periportal oedema
(arrows) indicative of acute hepatitis
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oedema within the pancreas (Fig. 6) [34]. Similarly,
necrotising pancreatitis is best seen on CT and has features
of pancreatic inflammation and fluid collection in addition to
the appearance of necrotic tissue (Fig. 7) [35]. Areas of de-
creased enhancement on CT and MR imaging can indicate
necrosis of pancreatic tissue [36]. MRI can be helpful in grad-
ing the severity of acute pancreatitis, determining the presence
and extent of necrosis, and may be more sensitive in the char-
acterisation of peripancreatic collections [37, 38]. Visualisa-
tion of the pancreas via US imaging is often difficult because
of patient body habitus and overlying bowel gas [39]. Thus,
US evaluation of pancreatitis is often limited to the identifica-
tion of peripancreatic fluid collection as well as hypoechoic
lesions indicating necrotic changes [39].
Pancreatic atrophy
Pancreatic atrophy is a possible adverse effect of cancer ther-
apy. In the literature, it has been reported that long-term use of
sorafenib is correlated with pancreatic atrophy [40]. Ganten
et al. explored the relationship between extended sorafenib
therapy and pancreatic atrophy and reported a mean pancreatic
volume loss of 25 % in hepatocellular carcinoma patients
being treated with long-term sorafenib [40]. Hescott examined
the pancreatic volume of two patients undergoing long-term
sorafenib treatment and reported similar findings of 20 and
35 % irreversible reduction in pancreatic volume [41].
Atrophy is detectable as soon as 3 months after initiation
of sorafenib therapy but may not present until as late as
2–3 years following treatment [40, 41].
Pancreatic atrophy can be best detected using CT and is
often accompanied by fatty infiltration of the pancreas [42].
Measurement of pancreatic volume can be used to quantita-
tively monitor progression and/or improvement of atrophy
and is commonly obtained by the Bsummation-of-areas^
method in which the pancreatic tissue area from each CT slice
is calculated and multiplied by slice thickness [43]. The
volume of all the pancreatic slices is combined to yield
the total pancreatic volume. Additionally, pancreatic size
can also be evaluated by measuring the linear dimensions,
such as the anteroposterior diameter, of the pancreatic head,
body, and tail (Fig. 8) [44].
Other pancreatic changes
Other pancreatic changes that have been observed include
fatty replacement of pancreatic tissue over the course
of cancer therapy and cystic changes in the pancreas
(Figs. 9 and 10). The evidence of the relationship of these
findings to specific agents is lacking in the literature; however,
these changes have been observed in our institution in patients




Cholecystitis is inflammation of the gallbladder. Symptoms
include right upper quadrant abdominal pain, fever, nausea,
and vomiting. There is growing evidence in the literature as-
sociating the use of targeted therapeutic agents with acute
acalculous cholecystitis, particularly everolimus and sunitinib
[45, 46]. Tirumani et al. examined the use of molecular-
targeted therapies (sunitinib, bevacizumab, everolimus, and
sorafenib) and associated gallbladder complications and found
acute cholecystitis in 66 % of patients with variable onset
between 2 weeks and 5 months [47]. These patients ultimately
Fig. 6 A 59-year-old female patient with stage IV non-small cell lung
carcinoma (NSCLC) and known metastatic disease to the adrenal glands
treated with carboplatin, premetrexed, and bevacizumab. a Axial
contrast-enhanced CT shows a normal pancreas prior to chemotherapy.
b Post-treatment axial contrast-enhanced CT demonstrating diffuse
oedema and parenchymal enlargement (arrow) consistent with the
development of acute interstitial pancreatitis
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Fig. 7 An 11-year-old male with
acute lymphoblastic leukaemia on
combination therapy that includes
L-asparaginase. a, b Axial and
coronal CT images, respectively,
show “walled-off” necrosis
(arrows) of the pancreas
Fig. 8 A 51-year-old female with stage IIIc ovarian cancer treated with
bevacizumab. a Axial contrast-enhanced CT of the pancreas pre-
chemotherapy with normal findings (arrow). b Repeat axial contrast-
enhanced CT 11 months after initiation of chemotherapy shows marked
pancreatic atrophy as well as fatty replacement (arrow)
Fig. 9 A 57-year-old female with leimyosarcoma treated with ifosfamide,
mesna, and doxorubicin. a Pre-chemotherapy axial contrast-enhanced CT
shows minimal fatty replacement of the pancreas. b Diffuse fatty
replacement of the pancreas (arrows) is noted on axial contrast-enhanced
CT performed 3 years later following cessation of chemotherapy
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required dose reduction, temporary discontinuation of the
therapy, or permanent discontinuation of the therapy with
50% requiring either cholecystectomy or cholecystotomy [47].
US is the imaging modality of choice to diagnose acute
acalculous cholecystitis. Sonographic findings of therapy-
induced acalculous cholecystitis include gallbladder wall thick-
ening (>3 mm), gallbladder distension, and pericholecystic fluid
in the absence of cholelithiasis [48]. Findings associated with
cholecystitis on CT include gallbladder distension (>40 mm),
fat stranding, hyperaemia, and pericholecystic free fluid
(Fig. 11) [48].
Biliary inflammation
Oncologic agents are mainly excreted through the kidneys or
the bile. Biliary excretion of certain oncologic agents may
cause changes in the biliary epithelium leading to biliary en-
hancement on imaging. Common chemotherapeutic agents
that are excreted through the bile include L-asparaginase,
doxorubicin, epirubicin, and paclitaxel [49]. Common
targeted therapeutics excreted through the bile include soraf-
enib and sunitinib [49]. Excretion of these therapeutic agents
may have adverse effects on the epithelium causing irritation,
thickening, and inflammation, which can be visualised as en-
hancement on CT and MR imaging (Figs. 12 and 13).
Biliary sclerosis
Chemotherapy-induced biliary sclerosis (CIBS) is a well-
known toxicity associated with hepatic arterial infusion pump
chemotherapy (HAIPC) with floxuridine [50]. Chemothera-
peutic agents can cause CIBS through adverse toxicity on
the biliary system or ischaemic changes to the pericholangitic
venous plexus, leading to stricture of the biliary ducts [7]. Ito
et al. examined the incidence of CIBS following HAIPC with
floxuridine and found 5.5 % incidence in patients receiving
HAIPC after hepatectomy and 2 % incidence in patients re-
ceiving HAIPC for unresectable disease [51]. CIBS can be
managed with alternating infusion of an intrahepatic steroid
or reduction in the chemotherapeutic dose while some cases
may require stenting or dilatation [7].
The imaging findings of biliary sclerosis resemble those of
primary sclerosing cholangitis and include a thickened and
enhanced bile duct wall, bile duct stricture with the lumen
measuring less than 3 mm, and periductal oedema [7, 52].
The gold standard imaging modality for detecting biliary
sclerosis is endoscopic retrograde choloangiopancreatography
(ERCP) [52]. ERCP is excellent for visualising the biliary tree
and has high sensitivity for detecting dilatations and strictures of
the biliary tree. Magnetic resonance cholangiopancreatography
(MRCP) is non-invasive and offers similar imaging advantages
as ERCP, but without the risks that ERCP has such as infection
and bleeding [52]. The use of ERCP allows for interventional
steps to be taken if necessary such as stenting and biliary stric-
ture dilatation while MRCP reduces the risk of complications
because of its non-invasive nature [52].
Biliary stasis
In addition to the biliary enhancement, biliary stasis has been
noted in our practice after initiation of tamoxifen and doxoru-
bicin. Biliary stasis is a condition in which bile cannot be
excreted from the liver into the duodenum and causes subse-
quent formation of biliary sludge and biliary dilatation [53].
Cholestasis may present with a number of symptoms includ-
ing scleral icterus and pruritis; however, drug-induced chole-
stasis may be asymptomatic with elevated alkaline phospha-
tase as the onlymanifestation [54]. US is the primary modality
used for diagnosing biliary stasis and is characterised by
Fig. 10 A 75-year-old male with lung adenocarcinoma receiving tarceva
chemotherapy. a Axial contrast-enhanced CT image performed prior to
initiation of chemotherapy treatment shows normal pancreatic features. b
Axial contrast-enhanced CT performed following 2 years of
chemotherapy shows the progression and development of multiple low-
attenuating cystic lesions (arrows)
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dilatation of the common bile duct (>7 mm) [53]. CT, cholan-
giography, and MR may be used to confirm biliary dilatation
as well as the presence of tumefactive sludge (Fig. 14) [53].
Additionally, MR imaging is the modality of choice for non-
invasive visualisation of the biliary tree and is useful in the
diagnosis of many biliary conditions [53].
Effects of localised therapy
Transcatheter arterial chemoembolisation (TACE) is a widely
used treatment for hepatocellular carcinoma. TACE is a pro-
cedure that involves transarterial administration of a mixture
of anticancer agents, such as doxorubicin or cisplatin, and
Fig. 11 A 54-year-old male with
stage IV non-small cell lung
cancer status post chemotherapy
treatment with cisplatin and
premetrexed. a, b Axial and
sagittal contrast-enhanced CT
images, respectively, show a
distended gallbladder with diffuse
gallbladder wall thickening
(arrows) consistent with acute
acalculous cholecystitis
Fig. 12 An 81-year-old female with stage IV recurrent squamous
NSCLC treated with carboplatin, gemcitabine tarceva, and abraxane. a,
b Axial and coronal contrast-enhanced CT images, respectively,
demonstrate a mildly dilated common bile duct (arrows) with thickened
enhancing walls consistent with biliary epithelial irritation
Fig. 13 A 39-year-old male with non-Hodgkin’s lymphoma treated with
doxorubicin. Coronal post-contrast MR image shows the thickened,
enhancing biliary wall (arrow) of the common bile duct consistent with
biliary inflammation
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iodised oil followed by embolising particles [55]. This allows
for local administration of chemotherapeutic agents directly to
tumours.
There are a number of imaging appearance changes that
present following TACE. On CT, portions of the tumour that
retain and accumulate iodised oil are necrotic and appear as
non-enhancing foci while enhancing foci indicate viable tissue
that may require additional treatment [55]. Kim et al. evaluat-
ed the value of the unenhanced phase in assessing HCC after
TACE and found that the use of the unenhanced phase could
improve the detection of viable tumour tissue with viable
HCC appearing hyperattenuating or isoattenuating on the he-
patic arterial phase and hypoattenuating on the unenhanced
phase [56]. However, accumulation of iodised oil may gener-
ate considerable beam-hardening artefacts on CT that are not
present on MRI [57]. In cases where there is a significant
amount of iodised oil, MR imaging plays a vital role because
of the artefact that appears on CT, resulting in difficulty de-
tecting tumours using this modality [57]. On MRI, necrotic
tissue will not demonstrate contrast enhancement while resid-
ual tumours will appear as hyperintense lesions [58].
Awareness of the normal imaging findings after TACE
will allow for better recognition of pathologic changes
associated with post-TACE complications. The adverse effects
of TACE have been well documented in the literature and
include hepatic abscess, hepatic failure, pancreatitis, and bile
duct injury [59].
Hepatic abscess
Hepatic abscess is a rare complication that can occur after
TACE and may develop secondary to bacterial seeding of
bilomas or from the necrotic core of an embolised hepatic
tumour [60]. Marelli et al. found liver abscess formation in
only 1.3 % of patients with VanderWalde reporting that pa-
tients with a history of bilioenteric anastomosis or biliary
reconstruction are at greatest risk for developing abscesses
[61, 62]. Woo et al. performed a study observing liver
abscess formation after the TACE procedure with doxoru-
bicin, iopamidol, and absorbable gelatin sponge embolisa-
tion in patients with bilioenteric anastomoses and found
that abscesses formed in 12 of 25 patients, significantly higher
than the 1.3 % reported for the general patient population [63].
Moreover, Woo et al. reported that particulate embolisation or
oily portogram significantly elevated the incidence of liver ab-
scess [63]. Hepatic abscess formation may appear at 2 weeks
post TACE and most can be treated successfully with a combi-
nation of percutaneous drainage and antibiotic therapy [60, 62].
Hepatic abscesses can be diagnosed with the highest sen-
sitivity on CT imaging and present as hypoattenuating lesions
with peripheral rim enhancement; however, imaging of the
post-TACE liver commonly reveals gas formation within
the areas of embolisation, which may confound hepatic
abscess diagnosis and require aspiration for accurate diag-
nosis [60, 64]. Additionally, MRI may play a helpful role
in the detection, characterisation, and evaluation of liver
abscesses because of its multiplanar capability and sensi-
tivity to small differences in tissue composition [65].
Hepatic failure
Hepatic failure following TACE is dependent on the baseline
hepatic function, with a higher incidence of liver failure in
patients with Child C liver disease compared with B and A
[60]. Due to the increased risk of complications, most individ-
uals with Child C liver disease will not be accepted for TACE.
Huang et al. conducted a prospective study finding acute liver
failure in 13.4 % of patients with HCC following TACE per-
formed with doxorubicin, Lipiodol, and Gelfoam cube embo-
lisation [66] Acute liver failure was previously established as
increased bilirubin ≥2 mg/dl, increased Child-Pugh score ≥2,
or ascites within 14 days of the procedure [66]. Additionally,
Fig. 14 A 60-year-old female
with recurrent ovarian cancer
treated with a multi-drug
chemotherapy regimen, which




sludge (arrow) within the gall
bladder lumen. b Repeat coronal
contrast-enhanced CT 6 months
later shows progression of
tumefactive sludge (arrows) and
enhancing mildly thickened
gallbladder wall changes,
consistent with biliary stasis
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Lu et al. investigated liver function damage following
superselective TACE with low-dose versus conventional-
dose anticancer drugs in HCC patients. Patients either re-
ceived low or conventional dose mitomycin C, epirubicin,
and carboplatin [66]. Anticancer drugs were administered
with Lipiodol followed by either gelatin sponge or polyvinyl
alcohol (PVA) particle embolisation [66]. Lu et al. found that
both doses worsened liver function, which was evaluated with
Child-Pugh scores, total bilirubin, albumin, and alanine ami-
notransferase [66]. However, the conventional dose caused
more severe impairment of liver function, suggesting that he-
patic failure from TACE may be dependent on chemothera-
peutic agent dosing [66].
Acute hepatic failure is primarily diagnosed clinically and
confirmed with laboratory testing. Prolonged PT/INR, elevated
aminotransferases, elevated bilirubin, and decreased platelet
count are among the abnormalities that may be detected with
laboratory tests [67]. Although the role of imaging is often
limited, signs suggestive of hepatic failure can be seen on US,
CT, andMR imaging. OnUS, liver failure presents as increased
hepatic echogenicity, ascites, nodularity, and segmental hyper-
trophy or atrophy [68]. Similarly, CT and MR can reveal asci-
tes, surface and parenchymal nodularity, heterogeneous liver
parenchyma, and segmental hypertrophy or atrophy [60, 68].
Pancreatitis
Pancreatitis is an uncommon but severe complication of
TACE. The incidence of this complication is rare, reported
in only 1.7 % of TACE patients, and may occur because of
reflux of chemoembolic agents to the pancreas [69, 70].
López-Benítez et al. investigated acute pancreatitis following
TACE and found acute pancreatitis 24 h after the procedure in
15.2 % of patients with non-selected embolisation. The num-
ber of procedures and volume of embolic material were found
to be the most significant factors associated with incidence
[71]. TACE-induced pancreatitis can be treated in the same
manner as pancreatitis from other causes [70].
Awareness of this complication following TACE warrants
routine monitoring of serum amylase and lipase and com-
plaints of abdominal pain may raise suspicions of acute pan-
creatitis related to TACE. As mentioned previously, pancrea-
titis may be characterised on CT by fluid collections,
peripancreatic fat stranding, or diffuse oedema within the pan-
creas. Areas of low attenuation within the pancreas can indi-
cate necrosis of pancreatic tissue.
Bile duct injury
Bile duct necrosis, biliary stricture, and biloma development
can occur following TACE because of ischaemic injury to the
biliary plexus [60]. Sakamoto et al. examined 972 patients to
investigate the incidence of biloma formation after TACE
[72]; 3.6 % patients developed intrahepatic biloma following
TACE therapy with the main risk factors being injection
of a suspension of anticancer drugs versus a mixture, bile
duct dilatation, and repeated chemoembolisations with a
frequency of less than 3 months [72]. Miyayama et al.
found main bile duct stricture with subsequent develop-
ment of bile duct dilatation in 4 % of HCC patients after
TACE performed with Lipiodol, epirubicin, and mitomycin
C followed by gelatin sponge particles [73]. The main risk
factor identified by Miyayama for development of main
bile duct stricture following TACE is selective TACE of
the caudate arterial branch and/or the medial segmental
artery of the liver [73].
Biliary strictures and bilomas commonly require endoscop-
ic or percutaneous drainage [60]. CT and MR can be used to
diagnose bile duct complications and portal vein obliteration
following TACE [74]. Bile duct injury can be seen as bile duct
dilatation and areas of decreased attenuation, which is indica-
tive of extrabiliary collection of bile [75]. MRCP allows for
excellent evaluation of the biliary tree and fluid collections.
When combined with a biliary contrast agent, MRCP is also
able to detect and localise bile duct leaks [76].
Conclusion
Cancer therapy includes a wide array of different types of treat-
ment, which includes chemotherapy, targeted therapy, and
catheter-directed chemoembolisation. The intrinsic toxicity of
these therapies contributes to their efficacy in combating
tumour growth, but also to the adverse effects they have on
healthy tissues. These toxic agents commonly affect the liver,
pancreas, and biliary system. The different treatment modalities
and anticancer agents can cause sinusoidal obstruction syn-
drome, fatty liver, pseudocirrhosis, pancreatitis, pancreatic atro-
phy, cholecystitis, biliary sclerosis, and biliary inflammation.
These changes may result in severe complications for patients
and even death. It is important to note that the imaging findings
associated with the cancer therapy complications discussed are
often similar to the findings seen with other causes of compli-
cations unrelated to cancer therapy, making clinical information
crucial when formulating treatment plans. Awareness and
familiarisation with the imaging features associated with these
cancer therapy-induced changes will allow for early detection of
these complications and improved patient management and
outcomes.
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